Mestinon 60 (Pyridostigmine Bromide)

The drug reversibly blocks acetylcholinesterase, the enzyme that degrades acetylcholine at the neuromuscular junction. By preserving acetylcholine, it enhances stimulation of muscle receptors, leading to stronger and more sustained muscle contractions.

The dosage of Mestinon 60 is individualized by the prescribing clinician based on disease severity, patient weight, renal function, and response to therapy. Patients should follow the exact regimen written on their prescription.

Safety data are limited; the product is classified as pregnancy category unknown. It should only be used during pregnancy or lactation if the potential therapeutic benefit justifies any possible risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mestinon 60 (pyridostigmine) is a reversible, short‑acting acetylcholinesterase inhibitor, often preferred for its predictable pharmacokinetics and oral formulation. Alternatives such neostigmine have similar mechanisms but differ in duration of action and route of administration, influencing clinical choice.

Store Mestinon 60 at ambient temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly sealed until use.

Mestinon 60 is taken orally, usually with a glass of water. It may be administered with or without food, but consistent timing relative to meals helps maintain stable blood levels. Patients should not crush or chew the tablets unless instructed otherwise.

The most critical adverse events include cholinergic crisis, which presents as severe muscle weakness and respiratory failure, and profound bradycardia that can lead to syncope. Prompt medical attention is required if these symptoms develop.

Patients with known hypersensitivity to pyridostigmine or any excipients in the tablet should avoid the product. Caution is also advised for individuals with severe asthma, uncontrolled cardiac arrhythmias, or significant renal impairment without appropriate dose adjustment.